These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1282504)

  • 1. Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response.
    Wiesmüller KH; Bessler WG; Jung G
    Int J Pept Protein Res; 1992; 40(3-4):255-60. PubMed ID: 1282504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.
    BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P
    Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.
    Le Gal FA; Prevost-Blondel A; Lengagne R; Bossus M; Farace F; Chaboissier A; Gras-Masse H; Engelhard VH; Guillet JG; Gahéry-Ségard H
    Int J Cancer; 2002 Mar; 98(2):221-7. PubMed ID: 11857412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocytes. Comparison of the costimulating support provided by helper T cells and lipoamino acid.
    Borges E; Wiesmüller KH; Jung G; Walden P
    J Immunol Methods; 1994 Aug; 173(2):253-63. PubMed ID: 7519223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection.
    Livingston BD; Crimi C; Grey H; Ishioka G; Chisari FV; Fikes J; Grey H; Chesnut RW; Sette A
    J Immunol; 1997 Aug; 159(3):1383-92. PubMed ID: 9233635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer.
    Xu DH; Zhou CH; Xia YP; Qiu ZY; Wu YZ; Jia ZC; Zhou W
    Acta Pharmacol Sin; 2007 May; 28(5):695-702. PubMed ID: 17439726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses.
    Oseroff C; Sette A; Wentworth P; Celis E; Maewal A; Dahlberg C; Fikes J; Kubo RT; Chesnut RW; Grey HM; Alexander J
    Vaccine; 1998 May; 16(8):823-33. PubMed ID: 9627940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipopeptide particles as the immunologically active component of CTL inducing vaccines.
    Tsunoda I; Sette A; Fujinami RS; Oseroff C; Ruppert J; Dahlberg C; Southwood S; Arrhenius T; Kuang LQ; Kubo RT; Chesnut RW; Ishioka GY
    Vaccine; 1999 Feb; 17(7-8):675-85. PubMed ID: 10067673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugates of synthetic lymphocyte-activating lipopeptides with segments from HIV proteins induce protein-specific antibody formation.
    Loleit M; Tröger W; Wiesmüller KH; Jung G; Strecker M; Bessler WG
    Biol Chem Hoppe Seyler; 1990 Oct; 371(10):967-75. PubMed ID: 1706188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes.
    Tam JP; Lu YA
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9084-8. PubMed ID: 2480595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation.
    Babu JS; Nair S; Kanda P; Rouse BT
    Vaccine; 1995 Dec; 13(17):1669-76. PubMed ID: 8719518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The optimization of helper T lymphocyte (HTL) function in vaccine development.
    Alexander J; Fikes J; Hoffman S; Franke E; Sacci J; Appella E; Chisari FV; Guidotti LG; Chesnut RW; Livingston B; Sette A
    Immunol Res; 1998; 18(2):79-92. PubMed ID: 9844827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides.
    Sauzet JP; Déprez B; Martinon F; Guillet JG; Gras-Masse H; Gomard E
    Vaccine; 1995 Oct; 13(14):1339-45. PubMed ID: 8585291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lipopeptides as novel adjuvants.
    Bessler WG; Jung G
    Res Immunol; 1992 Jun; 143(5):548-53; discussion 579-80. PubMed ID: 1439136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.
    Deres K; Schild H; Wiesmüller KH; Jung G; Rammensee HG
    Nature; 1989 Nov; 342(6249):561-4. PubMed ID: 2586628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide vaccines and peptide libraries.
    Wiesmüller KH; Fleckenstein B; Jung G
    Biol Chem; 2001 Apr; 382(4):571-9. PubMed ID: 11405221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of T-cell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis.
    Fonseca DP; Joosten D; Snippe H; Verheul AF
    Mol Immunol; 2000 Jun; 37(8):413-22. PubMed ID: 11090876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines.
    Shirai M; Chen M; Arichi T; Masaki T; Nishioka M; Newman M; Nakazawa T; Feinstone SM; Berzofsky JA
    J Infect Dis; 1996 Jan; 173(1):24-31. PubMed ID: 8537666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyvalent synthetic vaccines: relationship between T epitopes and immunogenicity.
    Jolivet M; Lise L; Gras-Masse H; Tartar A; Audibert F; Chedid L
    Vaccine; 1990 Feb; 8(1):35-40. PubMed ID: 1690488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.